2026.10.12
Meet Us at ESMO 2026.
First-in-Human Study of BH3120, a novel 4-1BB×PD-L1 Bispecific Antibody, as Monotherapy and in Combination with Pembrolizumab in Advanced Solid Tumors: Results from Monotherapy Dose-Escalation Part
- Presentation Number
- 1962Ep
- Presenter
-
Hye Ryun Kim, M.D. /
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Phase I dose-ranging update with HM97662, a dual EZH1/2 inhibitor, in biomarker-selected advanced or metastatic solid tumors
- Presentation Number
- 1051P
- Presenter
-
Lisi Elizabeth Lim /
Department of Medical Oncology, Ballarat Regional Integrated Cancer Centre, Ballarat, Victoria, Australia
Meet Us at ObesityWeek 2026.
HM500197, a Long-Acting Peptide based Myostatin Inhibitor, Improves Muscle Mass in Obese Mice
- Presentation Number
- TBD
- Session
- SMALL MOLECULES & PEPTIDES - Novel Drug Modalities, Nov. 15 at 14:30-15:30 PM
- Presenter
-
Jinyoung Kim /
Hanmi Pharm. Co., Ltd.
HM500197 Combination with Incretin-Based Therapy Preserves Skeletal Muscle Mass during Weight Loss
- Presentation Number
- TBD
- Session
- SMALL MOLECULES & PEPTIDES - Novel Drug Modalities, Nov. 15 at 14:30-15:30 PM
- Presenter
-
Jaehyuk Choi, Ph.D. /
Hanmi Pharm. Co., Ltd.
HM15275, a GLP-1/GIP/Glucagon Triple Agonist, Shows Anti-tumor Efficacy in an Obesity-Associated CRC
- Presentation Number
- TBD
- Session
- SMALL MOLECULES & PEPTIDES - Novel Drug Modalities, Nov. 16 at 14:30-15:30 PM
- Presenter
-
Wonki Kim, Ph.D. /
Hanmi Pharm. Co., Ltd.
Therapeutic Potential of HM15275, a Long-Acting GLP-1/GIP/Glucagon Triple Agonist, for Dyslipidemia
- Presentation Number
- TBD
- Session
- SMALL MOLECULES & PEPTIDES - Novel Drug Modalities, Nov. 16 at 14:30-15:30 PM
- Presenter
-
Yoon Keun Cho, Ph.D. /
Hanmi Pharm. Co., Ltd.
Efpeglenatide Attenuates Psoriasis in Both Obese and Lean Mice
- Presentation Number
- TBD
- Session
- SMALL MOLECULES & PEPTIDES - Novel Drug Modalities, Nov. 16 at 14:30-15:30 PM
- Presenter
-
Haemin Chon, M.D., Ph.D. /
Hanmi Pharm. Co., Ltd.
Meet Us at SITC 2026.
STING mRNA therapy with liver de-targeting reprograms immune-cold tumors to drive anti-tumor immunity
- Presentation Number
- 129
- Session
- Poster sessions, Nov. 6 at 10:00 AM
- Presenter
-
Solbi Shin, Ph.D. /
Hanmi Pharm. Co., Ltd.
Meet Us at EORTC-NCI-AACR (ENA) 2026.
Engineered p53 mRNA Analogs Restore Tumor Suppressor Function in TP53-Mutant Cancers
- Presentation Number
- 203
- Session
- Molecular Targeted Agents, Nov. 19 at 09:30 AM
- Presenter
-
Seung-Hyun Shin, Ph.D. /
Hanmi Pharm. Co., Ltd.
Engineered STING mRNA Analog Enables Dual Antitumor Activity Through Immune Activation and Tumor-Intrinsic Signaling
- Presentation Number
- 204
- Session
- Molecular Targeted Agents, Nov. 19 at 09:30 AM
- Presenter
-
Yong Ho Heo, Ph.D. /
Hanmi Pharm. Co., Ltd.
Structure-Based Optimization of Orally Bioavailable EP300-Selective Degraders
- Presentation Number
- PB-095
- Session
- Molecular Targeted Agents, Nov. 19 at 09:30 AM
- Presenter
-
Taegun Kim, Ph.D. /
Hanmi Pharm. Co., Ltd.
Meet Us at International mRNA Health Conference 2026.
A Functionally Enhanced Synthetic p53 mRNA Analog Restores p53 Activity and Suppresses TP53-Mutant Cancers
- Presentation Number
- 51
- Session
- Poster Session, Nov. 17 at 17:00 PM
- Presenter
-
ChangGyu Lim /
Hanmi Pharm. Co., Ltd.
